Skip to main content
Article thumbnail
Location of Repository

Outcomes of Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma in the Netherlands: A Nationwide Retrospective Analysis

By T. (Thijs) de Rooij, J.A. (Johanna A.) Tol, C.H.J. (Casper) van Eijck, D. (Djamila) Boerma, B.A. (Bert) Bonsing, K. (Koop) Bosscha, R. (Ronald) van Dam, M.G.W. (Marcel) Dijkgraaf, M.F. (Michael) Gerhards, H. (Harry) van Goor, E. (Erwin) van der Harst, I.H.J.T. (Ignace) de Hingh, G. (Geert) Kazemier, J.M. (Joost) Klaase, I.Q. (I. Quintus) Molenaar, G.A. (Gijs A.) Patijn, H.C. (Hjalmar) van Santvoort, J.J. (Joris J.) Scheepers, G. van der Schelling, E. (Egbert) Sieders, O.R.C. (Olivier) Busch and M.G. (Marc) Besselink


Background: Large multicenter series on outcomes and predictors of survival after distal pancreatectomy (DP) for pancreatic ductal adenocarcinoma (PDAC) are scarce. Methods: Adults who underwent DP for PDAC in 17 Dutch pancreatic centers between January 2005 and September 2013 were analyzed retrospectively. The primary outcome was survival, and predictors of survival were identified using Cox regression analysis. Results: In total, 761 consecutive patients after DP were assessed, of whom 620 patients were excluded because of non-PDAC histopathology (n = 616) or a lack of data (n = 4), leaving a total of 141 patients included in the study [45 % (n = 63) male, mean age 64 years (SD = 10)]. Multivisceral resection was performed in 43 patients (30 %) and laparoscopic resection was performed in 7 patients (5 %). A major complication (Clavien–Dindo score of III or higher) occurred in 46 patients (33 %). Mean tumor size was 44 mm (SD 23), and histopathological examination showed 70 R0 resections (50 %), while 30-day and 90-day mortality was 3 and 6 %, respectively. Overall, 63 patients (45 %) received adjuvant chemotherapy. Median survival was 17 months [interquartile range (IQR) 13–21], with a median follow-up of 17 months (IQR 8–29). Cumulative survival at 1, 3 and 5 years was 64, 29, and 22 %, respectively. Independent predictors of worse postoperative survival were R1/R2 resection [hazard ratio (HR) 1.6, 95 % confidence interval (CI) 1.1–2.4], pT3/pT4 stage (HR 1.9, 95 % CI 1.3–2.9), a major complication (HR 1.7, 95 % CI 1.1–2.5), and not receiving adjuvant chemotherapy (HR 1.5, 95 % CI 1.0–2.3). Conclusion: Survival after DP for PDAC is poor and is related to resection margin, tumor stage, surgical complications, and adjuvant chemotherapy. Further studies should assess to what extent prevention of surgical complications and more extensive use of adjuvant chemotherapy can improve survival

Year: 2016
DOI identifier: 10.1245/s10434-015-4930-4
OAI identifier:

Suggested articles

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.